Last €34.99 EUR
Change Today +0.85 / 2.49%
Volume 10.0
As of 1:44 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

zoetis inc (ZOE) Snapshot

Open
€34.25
Previous Close
€34.14
Day High
€35.36
Day Low
€34.25
52 Week High
11/18/14 - €35.67
52 Week Low
04/14/14 - €20.30
Market Cap
17.5B
Average Volume 10 Days
439.4
EPS TTM
--
Shares Outstanding
501.3M
EX-Date
11/3/14
P/E TM
--
Dividend
€0.29
Dividend Yield
0.62%
Current Stock Chart for ZOETIS INC (ZOE)

zoetis inc (ZOE) Details

Zoetis Inc. is engaged in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. It operates through four segments: United States, Europe/Africa/Middle East, Canada/Latin America, and Asia/Pacific. The company offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines that are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. It also provides medicated feed additives that offer medicines to livestock; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy, and dermatology products, as well as reproductive products. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey.

9,800 Employees
Last Reported Date: 03/26/14
Founded in 1952

zoetis inc (ZOE) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $825.0K
Group President and Executive Vice President
Total Annual Compensation: $605.0K
Executive Vice President and President of U.S...
Total Annual Compensation: $400.0K
President of Research & Development and Execu...
Total Annual Compensation: $400.0K
Compensation as of Fiscal Year 2013.

zoetis inc (ZOE) Key Developments

William Ackman May Sell Its Stake In Zoetis

William Ackman may sell stake in Zoetis Inc. (NYSE:ZTS) to Valeant Pharmaceuticals International, Inc. (TSX:VRX), according to people familiar with the matter. A spokesman for Zoetis said that the company got a call from William Ackman regarding the investment, but declined to comment on it. Valeant isn’t alone among potential suitors for Zoetis. Novartis AG (SWX:NOVN) and Bayer AG (BUSE:BAYER) also expressed interest in the company, people familiar with the matter have said.

Zoetis Inc. Announces Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 28, 2014 ; Provides Earnings Guidance for the Year 2014

Zoetis Inc. announced unaudited consolidated earnings results for third quarter and nine months ended September 28, 2014. For the quarter, the company reported revenue of $1,210 million, income before provision for taxes on income of $238 million, net income attributable to company of $166 million, basic and diluted of $0.33 million compared to the revenue of $1,103 million, income before provision for taxes on income of $185 million, net income attributable to company of $131 million, basic and diluted of $0.26 million for the same quarter a year ago. Adjusted net income attributable to company was $207 million or $0.41 per diluted share compared to the $172 million or $0.34 per diluted share for the same quarter year ago. For the nine months period, the company reported revenue of $3,465 million, income before provision for taxes on income of $665 million, net income attributable to company of $457 million, basic and diluted of $0.91 million compared to the revenue of $3,307 million, income before provision for taxes on income of $564 million, net income attributable to company of $399 million, basic and diluted of $0.80 million for the same period a year ago. Adjusted net income attributable to company was $587 million or $1.17 per diluted share compared to the $529 million or $1.06 per diluted share for the same period year ago. The company provided earnings guidance for the year 2014. For the year 2014, the company expected revenue in the range of $4,700 to $4,750 million, adjusted interest expense and other (income)/deductions of approximately $110 million, effective tax rate on adjusted income approximately 29%, adjusted diluted EPS in the range of $1.50 to $1.54; reported diluted EPS in the range of $1.16 to $1.20, adjusted net income in the range of $750 million to $770 million and reported net income attributable to company in the range of $580 million to $600 million.

Zoetis Inc. Declares Fourth Quarter 2014 Dividend on Common Stock, Payable on December 2, 2014

The board of directors of Zoetis Inc. declared a fourth quarter dividend payable to holders of the company’s common stock of $0.072 per share. The dividend is to be paid on December 2, 2014, to holders of record on November 5, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZOE:GR €34.99 EUR +0.85

ZOE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €117.17 EUR +3.34
ImmuCell Corp $4.66 USD -0.2875
Parnell Pharmaceuticals Holdings Pty Ltd $4.49 USD -0.11
Valneva SE €4.50 EUR +0.08
Virbac SA €175.75 EUR -5.00
View Industry Companies
 

Industry Analysis

ZOE

Industry Average

Valuation ZOE Industry Range
Price/Earnings 39.1x
Price/Sales 4.7x
Price/Book 16.1x
Price/Cash Flow 35.3x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZOETIS INC, please visit www.zoetis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.